Our agenda is expertly curated by an experienced team of producers with an expansive global network.
The Festival of Biologics is your opportunity to hear from industry leaders, global regulators and world-renowned academics at the forefront of innovation. Join us for 3 days of cutting-edge insights into the latest industry developments.
Create your personal agenda –check the favourite icon
Senior Representative, Roche
Senior Representative, GeneData
Senior Representative, FUJIFILM Diosynth
Senior Representative, Carterra
Senior Representative, Genovac
Senior Representative, ATUM
Senior Representative, XTALPI
Senior Representative, ATUM
Senior Representative, Selvita
Caibin Sheng, Data scientist, machine learning, computational oncology, GV20 Therapeutics (RESERVED)
Thebiologics CDMOMarket size is expected to grow from USD 13.58 billion in 2023 to USD 24.77 billion by 2028, at a CAGR of 12.78%. This growth is primarily driven by significant increase in outsourcing development and manufacturing activities by biotech as well as small and medium-sized pharmaceutical companies, to accelerate their biologic assets (e.g. bispecifics, mAbs and other recombinant proteins) into clinic and avoid the investment risk in capital-intensive manufacturing facilities. To stay competitive, biologics CDMO require not only high technical capability and globally compliant manufacturing facilities, but also unmatched agility and customer advocacy in their DNA to drive desired outcomes for their clients.
This talk will cover the 5 essential and fundamental elements (with examples), that are required for any CDMO to successfully deliver client programs and help them evolve from a mere service provider to a true value partner.
Senior Representative, Genscript Probio
Senior Representative, Sapio Life Sciences
Senior Representative, Veraxa
Senior Representative, Lonza
Senior Representative, Heidelberg Pharma
Senior Representative, Icosagen
Senior Representateive, OMNIAB
Senior Representative, Lonza
The design of potent multispecific immune cell engager based on the Ichnos BEAT® platform relies on the identification of diverse and developable common light chain (cLC) Fabs. The Ichnos discovery engine will be presented: cLC Fab discovery by phage and mammalian display; screening for optimal affinity, specificity and developability and automated architecture exploration based on functional screening. The design, generation and validation of a state-of-the-art antibody phage display library as a source of diverse cLC Fab will be highlighted.
Create your personal agenda –check the favourite icon
Senior Representative, GeneData
Overcoming the tumour microenvironment for effective immunotherapy Opportunities and challenges with multiplex immunofluorescence technologies for immunotherapy A new era of autoimmune disease treatment using mRNA Challenges in Immunotherapy Clinical Trial Design Advances in allogenic cell therapy Biomarkers in Translational Medicine Sustainability of the industry Pipeline development The impact of Interchangeability on biosimilar development Embedding the patient voice in clinical trial design Site Relationships Formulation development strategies Drug Substance Development StrategiesSenior Representative, University of Sheffield
Senior Representative, Q2 Solutions
Senior Representative, Sphere Fluidics
Senior Representative, Bio-Techne
Senior Representative, Twist Bioscience
Senior Representative, Excell Gene
Senior Representative, Refeyn
This presentation will cover:
· Introduction to the mHTX process that allows for design, generation, and expression tests of hundreds of constructs in parallel, followed by purification screen for selected panel of up to 96 molecules.
· Challenges encountered while developing robust, high-throughput and automation friendly methodologies as well as data capture solutions enabling efficient data mining and reuse.
· Examples how mHTX was instrumental for delivering both secreted and membrane protein reagents as well as identifying optimal constructs for cellular reagents generation.
Bioprocessing aids such as surfactants play a key role in maximising the output of production cell lines,alongside their importance in producing and maintaining a safe, efficacious, and high purity drug substancethroughout the downstream process. In this talk we shall discuss how Croda Pharma has developed andoptimised specific surfactants for upstream processing to insure consistency in performance and quality. Indownstream we will demonstrate how surfactants can be used for processes such as viral inactivation, cell lysis, antibody stability and purification. Learn more about the cutting-edge advancements that set CrodaPharma apart as an integral supplier to the biopharmaceutical industry, helping us to empower biologicsdelivery.
In this presentation, we will revisit the spectrum of biomarkers for lupus nephritis (LN), evaluating traditional perceptions and exploring novel insights. Through a critical examination of both classical and emerging biomarkers we aim to enhance and refine accessible diagnostic strategies in LN management.
Senior Representative, Nanotemper
Senior Representative, Alloy Therapeutics
Production of candidates, control molecules and targets at a preclinical stage is a critical activity for the development of therapeutic antibodies. Automation of certain processes (e.g., transfection, purification) can help achieve high protein production reproducibility and throughput to facilitate the identification of lead candidates. The Tecan Fluent liquid handling system was customized to perform automated transient transfection in 50-mL TubeSpin and plate formats. This platform is adapted for the transfection of complex, multispecific antibodies in the same run and led to improved titers compared to manual transfection.
Senior Representative, SGS
Create your personal agenda –check the favourite icon
The flexible BEAT® platform enables 5 or more functional modules to be combined into a single molecule. The biophysical properties of a complex multi-specific immune cell engager antibody can be quite different to the sum of its parts. Therefore, a developability screening cascade was developed starting from Fab or cytokine selection to multi-specific lead candidate selection. This was applied to identify ISB 2001, a first-in-class tri-specific BCMA and CD38 T cell engager now advancing in the clinic to treat Multiple Myeloma.
Cost-saving potential of biosimilars